About Event

Welcome to the ALS Drug Development Summit

Putting a spotlight on exciting pathways for therapeutic intervention, developing targeted therapeutics for stratified patient populations, and investigating alternative primary outcome measures, the ALS Drug Development Summit is uniquely positioned to provide strategic insight into accelerating effective therapies to patients. Hear from industry experts developing robust preclinical tools to establish therapeutic efficacy and leading the charge in correlating more sensitive markers of treatment response with clinical outcome to accurately reflect disease progression.

Unmissable Highlights for 2022:

https://www.als-drug-development.com/wp-content/uploads/sites/702/2022/01/cropped-MicrosoftTeams-image-7.png

Characterize pre-symptomatic ALS and harness new insights into genetically validated targets using stem cell technology with QurAlis and University of Miami to illuminate opportunities for early intervention

https://www.als-drug-development.com/wp-content/uploads/sites/702/2022/01/cropped-MicrosoftTeams-image-7.png

Dissect exciting targets in familial and sporadic disease with Sanofi, Eli Lilly, and ProMIS Neurosciences to evaluate novel pathways for intervention and assess progress in clinical trials

https://www.als-drug-development.com/wp-content/uploads/sites/702/2022/01/cropped-MicrosoftTeams-image-7.png

Harness opportunities to integrate digital biomarkers into clinical trials in ALS with Mitsubishi Tanabe Pharma and Massachusetts General Hospital to integrate activity monitors, speech recording apps, and smartphone-powered platforms for remote monitoring

https://www.als-drug-development.com/wp-content/uploads/sites/702/2022/01/cropped-MicrosoftTeams-image-7.png

Get the latest updates on the HEALEY ALS Platform Trial and constructing clinical trials to test combination therapies with Massachusetts General Hospital, Cytokinetics, and NeuroSense Therapeutics to accelerate towards effective ALS treatments and greater access for patients

https://www.als-drug-development.com/wp-content/uploads/sites/702/2022/01/cropped-MicrosoftTeams-image-7.png

Define the next step in sensitive primary outcome measures with Biogen, Barrow Neurological Institute, and Brainstorm Cell Therapeutics to understand continued dialogue with regulators on outcome measures beyond ALSFRS-R